153 related articles for article (PubMed ID: 35140208)
1. Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy.
Xiao Y; Chen J; Zhou H; Zeng X; Ruan Z; Pu Z; Jiang X; Matsui A; Zhu L; Amoozgar Z; Chen DS; Han X; Duda DG; Shi J
Nat Commun; 2022 Feb; 13(1):758. PubMed ID: 35140208
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint blockade reprograms systemic immune landscape and tumor microenvironment in obesity-associated breast cancer.
Pingili AK; Chaib M; Sipe LM; Miller EJ; Teng B; Sharma R; Yarbro JR; Asemota S; Al Abdallah Q; Mims TS; Marion TN; Daria D; Sekhri R; Hamilton AM; Troester MA; Jo H; Choi HY; Hayes DN; Cook KL; Narayanan R; Pierre JF; Makowski L
Cell Rep; 2021 Jun; 35(12):109285. PubMed ID: 34161764
[TBL] [Abstract][Full Text] [Related]
3. SUMOylation inhibitors activate anti-tumor immunity by reshaping the immune microenvironment in a preclinical model of hepatocellular carcinoma.
Wang Z; Pan B; Su L; Yu H; Wu X; Yao Y; Zhang X; Qiu J; Tang N
Cell Oncol (Dordr); 2024 Apr; 47(2):513-532. PubMed ID: 38055116
[TBL] [Abstract][Full Text] [Related]
4. Noninvasively Deciphering the Immunosuppressive Tumor Microenvironment Using Galectin-1 PET to Inform Immunotherapy Responses.
Liu N; Yang X; Gao C; Wang J; Zeng Y; Zhang L; Yin Q; Zhang T; Zhou H; Li K; Du J; Zhou S; Zhao X; Zhu H; Yang Z; Liu Z
J Nucl Med; 2024 May; 65(5):728-734. PubMed ID: 38514084
[TBL] [Abstract][Full Text] [Related]
5. Multifunctional nanoparticle potentiates the in situ vaccination effect of radiation therapy and enhances response to immune checkpoint blockade.
Zhang Y; Sriramaneni RN; Clark PA; Jagodinsky JC; Ye M; Jin W; Wang Y; Bates A; Kerr CP; Le T; Allawi R; Wang X; Xie R; Havighurst TC; Chakravarty I; Rakhmilevich AL; O'Leary KA; Schuler LA; Sondel PM; Kim K; Gong S; Morris ZS
Nat Commun; 2022 Aug; 13(1):4948. PubMed ID: 35999216
[TBL] [Abstract][Full Text] [Related]
6. Combination with SGT-53 overcomes tumor resistance to a checkpoint inhibitor.
Kim SS; Harford JB; Moghe M; Rait A; Chang EH
Oncoimmunology; 2018; 7(10):e1484982. PubMed ID: 30288347
[TBL] [Abstract][Full Text] [Related]
7. Ultrasound combined with microbubble mediated immunotherapy for tumor microenvironment.
Wu Y; Li J; Shu L; Tian Z; Wu S; Wu Z
Front Pharmacol; 2024; 15():1304502. PubMed ID: 38487163
[TBL] [Abstract][Full Text] [Related]
8. Anti-Colon Cancer Activity of Copper-Doped Folate Carbon Dots/MnO
Liu M; Xia Q; Wu X; Jin S; Xie Y; Yan R; Jin Y; Wang Z
Bioconjug Chem; 2024 May; ():. PubMed ID: 38722674
[TBL] [Abstract][Full Text] [Related]
9. Editorial: Overcoming obstacles of cancer immunotherapy: the important role of emerging nanomedicine.
Jiang A; He W; Yao Y
Front Oncol; 2024; 14():1406244. PubMed ID: 38646437
[No Abstract] [Full Text] [Related]
10. Strategies to optimize the promise of checkpoint-targeted anti-cancer therapy.
Rapoport BL; Anderson R
Immunotherapy; 2024 May; ():. PubMed ID: 38717385
[No Abstract] [Full Text] [Related]
11. mRNA-based cancer therapeutics.
Liu C; Shi Q; Huang X; Koo S; Kong N; Tao W
Nat Rev Cancer; 2023 Aug; 23(8):526-543. PubMed ID: 37311817
[TBL] [Abstract][Full Text] [Related]
12. CREBZF mRNA nanoparticles suppress breast cancer progression through a positive feedback loop boosted by circPAPD4.
Zhou B; Xue J; Wu R; Meng H; Li R; Mo Z; Zhai H; Chen X; Liu R; Lai G; Chen X; Li T; Zheng S
J Exp Clin Cancer Res; 2023 Jun; 42(1):138. PubMed ID: 37264406
[TBL] [Abstract][Full Text] [Related]
13. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.
Liu Y; Xun Z; Ma K; Liang S; Li X; Zhou S; Sun L; Liu Y; Du Y; Guo X; Cui T; Zhou H; Wang J; Yin D; Song R; Zhang S; Cai W; Meng F; Guo H; Zhang B; Yang D; Bao R; Hu Q; Wang J; Ye Y; Liu L
J Hepatol; 2023 Apr; 78(4):770-782. PubMed ID: 36708811
[TBL] [Abstract][Full Text] [Related]
14. The role of nanotherapy in head and neck squamous cell carcinoma by targeting tumor microenvironment.
Zhang Y; Dong P; Yang L
Front Immunol; 2023; 14():1189323. PubMed ID: 37292204
[TBL] [Abstract][Full Text] [Related]
15. Polymeric nanoparticle gel for intracellular mRNA delivery and immunological reprogramming of tumors.
Neshat SY; Chan CHR; Harris J; Zmily OM; Est-Witte S; Karlsson J; Shannon SR; Jain M; Doloff JC; Green JJ; Tzeng SY
Biomaterials; 2023 Sep; 300():122185. PubMed ID: 37290232
[TBL] [Abstract][Full Text] [Related]
16. Increased CD8+ T-cell Infiltration and Efficacy for Multikinase Inhibitors After PD-1 Blockade in Hepatocellular Carcinoma.
Kikuchi H; Matsui A; Morita S; Amoozgar Z; Inoue K; Ruan Z; Staiculescu D; Wong JS; Huang P; Yau T; Jain RK; Duda DG
J Natl Cancer Inst; 2022 Sep; 114(9):1301-1305. PubMed ID: 35288743
[TBL] [Abstract][Full Text] [Related]
17. Recent Findings on Therapeutic Cancer Vaccines: An Updated Review.
Sheikhlary S; Lopez DH; Moghimi S; Sun B
Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672519
[TBL] [Abstract][Full Text] [Related]
18. Surface engineering of lipid nanoparticles: targeted nucleic acid delivery and beyond.
Lin Y; Cheng Q; Wei T
Biophys Rep; 2023 Oct; 9(5):255-278. PubMed ID: 38516300
[TBL] [Abstract][Full Text] [Related]
19. Potential role of p53 deregulation in modulating immune responses in human malignancies: A paradigm to develop immunotherapy.
Chauhan S; Jaiswal S; Jakhmola V; Singh B; Bhattacharya S; Garg M; Sengupta S
Cancer Lett; 2024 Apr; 588():216766. PubMed ID: 38408603
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy resistance in solid tumors: mechanisms and potential solutions.
Lefler DS; Manobianco SA; Bashir B
Cancer Biol Ther; 2024 Dec; 25(1):2315655. PubMed ID: 38389121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
